As of March 24, there were 22 cases of cerebral venous sinus thrombosis and another eight cases of thrombosis with low platelets.
The UK medical regulator said Saturday that out of 30 people who suffered blood clots after receiving the Oxford-AstraZeneca vaccine, seven have died.
The Netherlands was the lastest European countries to stop using the AstraZeneca vaccine to vaccinate people under the age of 60, amid fears of a link between it and the incidence of rare blood clots. And even if they are, British and European regulators have said they were so rare that the vaccine should continue to be used. Scientists have said that case counts would inevitably rise among vaccinated people as doctors began looking more closely for the condition.
"In real terms - if there is a risk [of blood clots from the vaccine] - it is miniscule by comparison to the risk of Covid".
The Medicines and Healthcare Regulatory Agency said the risk associated with this type of blood clot is "very small" and that the public should continue to take up the vaccine when offered it.
Britain, where the vaccine was developed with Oxford University, has been one of the countries worst-hit by coronavirus with almost 127,000 dead. "We have to be able to trust the vaccines", Merkel said.
Professor Adam Finn, from the University of Bristol, said: "The report states that these cases are being very carefully investigated to better understand whether or not they may have any causal relationship with vaccination".
Regulators said they had received no reports of such clotting events after the use of the Pfizer/BioNTech vaccine.
The move came after five new cases were recorded in the Netherlands in women aged 25 to 65 years, one of whom died.
On March 18, the United Kingdom medicines regulator said that there had been five cases of a rare brain blood clot among 11 million administered shots.
"That's still up in the air", said Fauci when asked whether the USA will use the AstraZeneca vaccine doses.
The UK in June 2020 ordered 100 million doses of the Oxford-AstraZeneca vaccine and supported its development.
On Thursday, Germany's immunisation commission, the STIKO, recommended that anyone younger than 60 who received an initial vaccination with AstraZeneca be given either Pfizer-BioNTech or Moderna shots as their second vaccine doses.